Skip to content
PeptideAgent

Peptides for immune support and immune deficiency: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Thymosin alpha-1 is the only immune peptide with substantial human trial data, including controlled trials in chronic hepatitis B and severe sepsis, and it is approved in more than 30 countries but not in the United States. Thymalin has small uncontrolled Russian reports. For healthy people, no peptide has been shown to prevent infections.

Evidence: Strongest: Human RCT evidence4 peptides gradedVerified: Verified Sep 22, 2026

Do peptides help with immune support and immune deficiency?

4 peptides are graded for immune support and immune deficiency on this page. The strongest grade is human RCT evidence, for thymosin alpha-1. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for immune support and immune deficiency?

Vaccination on schedule, sleep, nutrition, and physical activity; evaluate recurrent, severe, or unusual infections for primary or secondary immunodeficiency; immunoglobulin replacement and preventive antimicrobials for confirmed antibody deficiency under an immunologist.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for immune support and immune deficiency?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Immune support and immune deficiency with evidence grades
PeptideEvidence for this useNote
Thymosin alpha-1Evidence: Human RCT evidenceImproved hepatitis B viral response in a 98 patient trial; in severe sepsis (n = 361), 28 day mortality was 26.0% versus 35.0%, which was not statistically significant; FDA placed it in 503A Category 2 in 2023. [1] [2]
ThymalinEvidence: Human observational evidenceUncontrolled Russian reports of faster lymphocyte and inflammatory marker recovery, including in hospitalized COVID-19 patients; not approved outside Russia. [4]
ThymulinEvidence: Animal-only evidenceZinc dependent thymic hormone studied mainly in rodents for immune effects; no human immune function study. [6]
LL-37Evidence: Animal-only evidenceHuman antimicrobial peptide with broad lab and animal activity; no human study of injected LL-37 for immunity. [5]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for immune support and immune deficiency?

Thymosin alpha-1 has the strongest evidence among the peptides graded here, at human RCT evidence. Improved hepatitis B viral response in a 98 patient trial; in severe sepsis (n = 361), 28 day mortality was 26.0% versus 35.0%, which was not statistically significant; FDA placed it in 503A Category 2 in 2023. [1] [2]

Is any peptide FDA approved for immune support and immune deficiency?

No. None of the peptides graded for immune support and immune deficiency is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [7]

Has any peptide been tested in a randomized trial for immune support and immune deficiency?

Yes, for Thymosin alpha-1. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2]

From the blog

Sources

  1. [1]Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialPubMed 9581695, 1998
  2. [2]The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialPubMed 23327199, 2013
  3. [3]Historical review of thymosin alpha 1 in infectious diseasesPubMed 26098768, 2015
  4. [4]Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19PubMed 33575961, 2021
  5. [5]A comprehensive summary of LL-37, the factotum human cathelicidin peptidePubMed 23246832, 2012
  6. [6]Contribution of zinc and other metals to the biological activity of the serum thymic factorPubMed 6957870, 1982
  7. [7]Drugs@FDA: FDA-approved drugs databaseFDA